$33.50
4.45% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US4158581094
Symbol
HROW
Sector
Industry

Harrow Health, Inc. Stock price

$33.50
-8.97 21.12% 1M
+12.50 59.52% 6M
+22.30 199.11% YTD
+22.55 205.94% 1Y
+24.42 268.94% 3Y
+25.62 325.13% 5Y
+26.07 350.87% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.56 4.45%
ISIN
US4158581094
Symbol
HROW
Sector
Industry

Key metrics

Market capitalization $1.19b
Enterprise Value $1.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 432.96
EV/Sales (TTM) EV/Sales 7.78
P/S ratio (TTM) P/S ratio 7.05
P/B ratio (TTM) P/B ratio 20.71
Revenue growth (TTM) Revenue growth 48.15%
Revenue (TTM) Revenue $169.14m
EBIT (operating result TTM) EBIT $-8.57m
Free Cash Flow (TTM) Free Cash Flow $3.04m
Cash position $72.60m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 6.22
EV/Sales forward 6.86
Short interest 11.40%
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Harrow Health, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Harrow Health, Inc. forecast:

Buy
100%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
169 169
48% 48%
100%
- Direct Costs 46 46
35% 35%
27%
123 123
54% 54%
73%
- Selling and Administrative Expenses 108 108
74% 74%
64%
- Research and Development Expense 11 11
169% 169%
6%
4.04 4.04
71% 71%
2%
- Depreciation and Amortization 13 13
24% 24%
7%
EBIT (Operating Income) EBIT -8.57 -8.57
343% 343%
-5%
Net Profit -33 -33
135% 135%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Positive
Seeking Alpha
15 days ago
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and re...
Neutral
Business Wire
about one month ago
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSR...
Neutral
Business Wire
about one month ago
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2...
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 315
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today